AUPH Aurinia Pharmaceuticals Inc.

NASDAQ
$16.44

Aurinia Pharmaceuticals Inc. (AUPH) is expected to report earnings on November 9, 2026, before the market open. The consensus earnings estimate is $0.21 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +3.2% since its last earnings release on August 6, 2026.

Aurinia Pharmaceuticals Beat Consensus Estimates
Thursday, August 6, 2026 · 8:00 AM ET
Earnings Date
3rd Quarter, Sep 2026
Nov 9
Monday · 8:00 AM ET
Earnings Whisper
-
vs $0.21
Rev est $87.2M
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $16.23

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Aurinia Pharmaceuticals Inc.

Aurinia Pharmaceuticals Inc is a biopharmaceutical company. Its focused on the development of its novel therapeutic immunomodulating drug candidate, voclosporin, for the treatment of lupus nephritis.

Sector

Healthcare

Industry

Drug Manufacturers/Other

Held By 2 ETFs, by dollar flow

Charts powered in part by Lightweight Charts™ by TradingView.